The firm will sell 855,000 shares of its common stock to three investors. It will also sell warrants to the same investors.
The new agreement brings Interpace's total insurance coverage for its thyroid assays to approximately 200 million patients.
The state has given its approval for the company to market its ThyGenX next-generation sequencing oncogene panel for indeterminate thyroid nodules.
Assessments of the firm's rapid molecular BRAF and EGFR tests by researchers in Italy and South Korea showed high sensitivity and a fast turnaround time.
The test analyzes the expression of 10 microRNAs to classify thyroid nodules as cancerous or benign following indeterminate results from fine-needle aspirate and biopsy samples.
Using a combination of exome sequencing, SNP arrays, and RNA sequencing, researchers found therapeutically informative mutations in most solid tumor cases tested.
Along with known contributors to thyroid cancer, researchers detected mutations that were associated with aggressive cases and metastasis.
When molecular testing did affect the surgical plan, it often led to overtreatment, according to the Johns Hopkins University School of Medicine team.
The diagnostics company said the number of tests accessioned during the quarter grew 60 percent year over year.
The test analyzes microRNA expression in indeterminate thyroid fine needle aspirate smears to differentiate benign thyroid nodules from malignant ones.
In Science this week: metagenomic-based technique for determining protein structure, and more.
An academic laments the rise of narcissism in the sciences, the Guardian reports.
Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.
The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.